Log in

NASDAQ:AQSTAquestive Therapeutics Stock Price, Forecast & News

$4.87
-0.12 (-2.40 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.73
Now: $4.87
$5.03
50-Day Range
$2.58
MA: $4.52
$6.44
52-Week Range
$1.41
Now: $4.87
$10.00
Volume789,916 shs
Average Volume1.66 million shs
Market Capitalization$163.53 million
P/E RatioN/A
Dividend YieldN/A
Beta3.62
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Read More
Aquestive Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AQST
CUSIPN/A
CIKN/A
Phone908-941-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$52.61 million
Book Value($0.62) per share

Profitability

Net Income$-66,250,000.00
Net Margins-139.64%

Miscellaneous

Employees232
Market Cap$163.53 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

How has Aquestive Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AQST shares have increased by 65.6% and is now trading at $4.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aquestive Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aquestive Therapeutics.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aquestive Therapeutics.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics Inc (NASDAQ:AQST) posted its earnings results on Tuesday, May, 5th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.02. The business had revenue of $8.77 million for the quarter, compared to analysts' expectations of $10.90 million. View Aquestive Therapeutics' earnings history.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $35-45 million, compared to the consensus revenue estimate of $41.4 million.

What price target have analysts set for AQST?

5 brokers have issued 1-year price objectives for Aquestive Therapeutics' stock. Their forecasts range from $8.00 to $31.00. On average, they expect Aquestive Therapeutics' stock price to reach $16.40 in the next year. This suggests a possible upside of 236.8% from the stock's current price. View analysts' price targets for Aquestive Therapeutics.

Has Aquestive Therapeutics been receiving favorable news coverage?

News stories about AQST stock have trended extremely negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aquestive Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAquestive Therapeutics.

Who are some of Aquestive Therapeutics' key competitors?

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Inovio Pharmaceuticals (INO), AbbVie (ABBV), Alibaba Group (BABA), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Roku (ROKU), Aimmune Therapeutics (AIMT), Outlook Therapeutics (OTLK), Applied Genetic Technologies (AGTC) and Anavex Life Sciences (AVXL).

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the following people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 62, Pay $859.98k)
  • Mr. John T. Maxwell, Sr. VP & CFO (Age 55, Pay $537.15k)
  • Mr. Daniel Barber, Sr. VP & COO (Age 44, Pay $639.97k)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 61)
  • Ms. Lori J. Braender Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 64)

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include DG Capital Management LLC (1.63%), JPMorgan Chase & Co. (1.23%), BlackRock Inc. (0.63%), Canada Pension Plan Investment Board (0.52%), Wedbush Securities Inc. (0.26%) and Oak Grove Capital LLC (0.21%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd and Theresa Wood. View institutional ownership trends for Aquestive Therapeutics.

Which institutional investors are selling Aquestive Therapeutics stock?

AQST stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, and Squarepoint Ops LLC. View insider buying and selling activity for Aquestive Therapeutics.

Which institutional investors are buying Aquestive Therapeutics stock?

AQST stock was acquired by a variety of institutional investors in the last quarter, including DG Capital Management LLC, Canada Pension Plan Investment Board, JPMorgan Chase & Co., Oak Grove Capital LLC, Wedbush Securities Inc., Creative Planning, UBS Group AG, and Tower Research Capital LLC TRC . Company insiders that have bought Aquestive Therapeutics stock in the last two years include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd, and Theresa Wood. View insider buying and selling activity for Aquestive Therapeutics.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $4.87.

How big of a company is Aquestive Therapeutics?

Aquestive Therapeutics has a market capitalization of $163.53 million and generates $52.61 million in revenue each year. The company earns $-66,250,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis. Aquestive Therapeutics employs 232 workers across the globe.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is www.aquestive.com.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.